EMAIL THIS PAGE TO A FRIEND

Proceedings of the National Academy of Sciences of the United States of America

Connexin hemichannels contribute to spontaneous electrical activity in the human fetal cortex.


PMID 25197082

Abstract

Before the human cortex is able to process sensory information, young postmitotic neurons must maintain occasional bursts of action-potential firing to attract and keep synaptic contacts, to drive gene expression, and to transition to mature membrane properties. Before birth, human subplate (SP) neurons are spontaneously active, displaying bursts of electrical activity (plateau depolarizations with action potentials). Using whole-cell recordings in acute cortical slices, we investigated the source of this early activity. The spontaneous depolarizations in human SP neurons at midgestation (17-23 gestational weeks) were not completely eliminated by tetrodotoxin--a drug that blocks action potential firing and network activity--or by antagonists of glutamatergic, GABAergic, or glycinergic synaptic transmission. We then turned our focus away from standard chemical synapses to connexin-based gap junctions and hemichannels. PCR and immunohistochemical analysis identified the presence of connexins (Cx26/Cx32/Cx36) in the human fetal cortex. However, the connexin-positive cells were not found in clusters but, rather, were dispersed in the SP zone. Also, gap junction-permeable dyes did not diffuse to neighboring cells, suggesting that SP neurons were not strongly coupled to other cells at this age. Application of the gap junction and hemichannel inhibitors octanol, flufenamic acid, and carbenoxolone significantly blocked spontaneous activity. The putative hemichannel antagonist lanthanum alone was a potent inhibitor of the spontaneous activity. Together, these data suggest that connexin hemichannels contribute to spontaneous depolarizations in the human fetal cortex during the second trimester of gestation.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C3595 Anti-Connexin-32 (106-124) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
C3470
Anti-Connexin-32 (265-279) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
AV36685
Anti-CX36 antibody produced in rabbit, IgG fraction of antiserum
SAB2100922
Anti-GJA9 antibody produced in rabbit, affinity isolated antibody
HPA010663
Anti-GJB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV36600
Anti-GJB1 antibody produced in rabbit, IgG fraction of antiserum
SAB2104320
Anti-GJB1 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
HPA014355
Anti-GJD2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2100925
Anti-GJD2 antibody produced in rabbit, affinity isolated antibody
C6344
Monoclonal Anti-Connexin-32 antibody produced in mouse, clone CXN-32, ascites fluid, buffered aqueous solution
C8093
Monoclonal Anti-Connexin-43 antibody produced in mouse, clone CXN-6, ascites fluid
SAB1403864
Monoclonal Anti-GJB1 antibody produced in mouse, clone 2B9, purified immunoglobulin, buffered aqueous solution
SAB1402208
Monoclonal Anti-GJB1 antibody produced in mouse, clone 1F5, purified immunoglobulin, buffered aqueous solution
SAB1412865
Monoclonal Anti-GJD2 antibody produced in mouse, clone 5E5, purified immunoglobulin, 1 mg/mL
78429
p-Phenylenediamine, ≥99.0% (GC/NT)
C6H8N2
P6001
p-Phenylenediamine
C6H8N2
78430
p-Phenylenediamine, technical, ≥97.0% (GC/NT)
C6H8N2
695106
p-Phenylenediamine, sublimed, ≥99%
C6H8N2